Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covidien Gains Barrett’s Esophagus Ablation Device Via Barrx Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.

You may also be interested in...



Covidien Ventures Into Capsule-Based Endoscopy With Given Imaging Acquisition

The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.

Covidien Buys superDimension: $300 Mil. Deal Targets Lung Cancer Screening Market

Acquired iLogic system includes planning and navigation software that generates three-dimensional images using patient CT scans, and disposable catheter-based tools for navigation and biopsy.

Covidien Plans April U.S. Launch Of Solitaire For Ischemic Strokes

Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT030758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel